Carfilzomib

[MAF] Carfilzomib Infusion 30 mg

1. Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses.

2. Carfilzomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy.

[MSHL] Carfilzomib Powder For Solution For Infusion 30 mg

1. Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses.

2. Carfilzomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy.

[MSHL] Carfilzomib Powder For Solution For Infusion 30 mg

1. Isatuximab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior therapies.

View legend

01/11/2025 Review of cancer drugs for previously treated multiple myeloma

The Ministry of Health’s Drug Advisory Committee has recommended:

• Carfilzomib 30 mg powder for solution for infusion;

• Ixazomib 3 mg and 4 mg capsules; and

• Pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules

for previously treated multiple myeloma in line with specific clinical criteria.

Carfilzomib, ixazomib and pomalidomide should be used in line with the recommended treatment regimens listed in the Annex.

Subsidy status

[R] Carfilzomib 30 mg powder for solution for infusion, ixazomib 3 mg and 4 mg capsules and pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) in line with the abovementioned indication.

[R] MAF assistance for carfilzomib will be implemented from 4 January 2022. MAF assistance for ixazomib and pomalidomide will be implemented from 1 September 2022.

[NR] MAF assistance does not apply to daratumumab 100 mg/5 ml and 400 mg/20 ml concentrate for solution for infusion and 1800 mg/15 ml solution for subcutaneous injection when used for previously treated multiple myeloma.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

View legend

DHCPL 04/11/2019 Kyprolis® (carfilzomib) and risk of progressive multifocal leukoencephalopathy and Hepatitis B virus reactivation

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration